Passage Bio, Inc. (PASG) Balance Sheet

NASDAQ: PASGAssets, liabilities, debt and equity over 8 years.

PASG balance sheet, 2025

December 31, 2025 · U.S. dollars

$62.3M assets = $43.5M liabilities + $18.8M equity

What it owns$62.3MCash & ST investments: $46.3M (74.3%)Cash & ST investments$46.3M · 74%Other current: $1.5M (2.3%)PP&E: $14.3M (22.9%)PP&E$14.3M · 23%Other non-current: $244,000 (0.4%)=How it is financed$62.3MCurrent liabilities: $23.1M (37.1%)Current liabilities$23.1M · 37%Other LT liabilities: $20.4M (32.8%)Other LT liabilities$20.4M · 33%Shareholders’ equity: $18.8M (30.1%)Shareholders’ equity$18.8M · 30%

Both columns are drawn to the same scale: what PASG owns equals what it owes plus shareholders’ equity. Hover a block for its value.

PASG financial health

Current ratio2.07
Comfortable · current assets cover current liabilities 2.07×
Debt / equity1.28
Moderate leverage · $1.28 of debt for each $1 of equity
Equity / assets30.1%
Balanced · of assets funded by shareholders
Cash / debt192.8%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

PASG balance sheet trends, 2018–2025

Passage Bio, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$33.5M2018$62.3M2025+9.3%/yr
Total liabilities$45.6M2018$43.5M2025−0.7%/yr
Shareholders’ equity−$12.2M2018$18.8M2025—
Cash & short-term investments$24.9M2018$46.3M2025+9.3%/yr
Total debt$27.1M2022$24.0M2025−4.0%/yr
Net cash (debt)$162.5M2022$22.3M2025−$140.2M
Working capital$33.1M2018$24.7M2025−$8.4M
Book value per share−$10.162018$5.912025—
Current ratio108.7920182.072025−106.72
Debt / equity0.1320221.282025+1.15
Shares outstanding1.2M20183.2M2025+14.9%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

PASG assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

PASG liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

PASG debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

PASG balance sheet

Passage Bio, Inc. annual balance sheet
20252024202320222021202020192018
Assets
Cash & short-term investments$46.3M$76.8M$114.3M$189.6M$315.8M$304.8M$158.9M$24.9M
Cash & equivalents$46.3M$37.6M$21.7M$34.6M$129.0M$135.0M$158.9M$24.9M
Short-term investments$0$39.2M$92.6M$155.0M$186.8M$169.8M——
Receivables$0$0$0$4.3M$6.2M$8.0M$0$0
Inventory$0$0$0$0$0$0$0$0
Other current assets$1.5M$2.1M$3.7M$3.2M$3.1M$4.3M$6.9M$8.5M
Total current assets$47.8M$78.8M$118.0M$197.0M$325.1M$317.2M$165.8M$33.4M
Property, plant & equipment (net)$14.3M$23.1M$32.2M$42.2M$23.8M$2.8M$1.1M$28,000
Goodwill & intangible assets$0$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0$0
Other non-current assets$244,000$463,000$433,000$4.3M$6.2M$8.0M$11.8M$34,000
Total assets$62.3M$102.4M$150.5M$243.5M$355.1M$328.0M$178.6M$33.5M
Liabilities
Accounts payable$1.1M$742,000$1.3M$4.1M$9.4M$5.3M$629,000$212,000
Short-term debt$3.6M$3.7M$3.4M$3.3M————
Deferred revenue$13.8M$8.2M——————
Total current liabilities$23.1M$19.4M$16.3M$18.4M$29.5M$21.2M$3.7M$307,000
Long-term debt$0$0$0$0$0$0$0$0
Lease obligations$24.0M$25.5M$26.3M$27.1M$0———
Other long-term liabilities$20.4M$21.8M$22.9M$23.8M$6.9M$2.1M$580,000$45.3M
Total liabilities$43.5M$41.2M$39.3M$42.2M$36.4M$23.3M$4.3M$45.6M
Shareholders' equity
Common stock & paid-in capital—$6,000$5,000$5,000$5,000$4,000$3,000$2,000
Retained earnings (deficit)−$704.8M−$659.2M−$594.5M−$492.4M−$356.3M−$170.9M−$58.7M−$13.0M
Accumulated other comprehensive income—$8,000−$43,000−$966,000−$413,000−$12,000−$230,605$0
Total shareholders' equity$18.8M$61.3M$111.3M$201.4M$318.7M$304.7M$174.4M−$12.2M
Key figures
Total debt$24.0M$25.5M$26.3M$27.1M————
Net cash (debt)$22.3M$51.3M$88.0M$162.5M————
Working capital$24.7M$59.5M$101.6M$178.7M$295.6M$296.0M$162.1M$33.1M
Tangible book value$18.8M$61.3M$111.3M$201.4M$318.7M$304.7M$174.4M−$12.2M
Book value per share$5.91$20.28$40.66$73.99$119.47$133.60$145.52−$10.16
Shares outstanding3.2M3.0M2.7M2.7M2.7M2.3M1.2M1.2M
Current ratio2.074.077.2210.7411.0214.9845.04108.79
Quick ratio2.013.966.9910.5610.9214.7743.1680.98
Debt / equity1.280.420.240.13————
Equity / assets30.1%59.8%73.9%82.7%89.7%92.9%97.6%−36.4%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 3, 2026); data from EODHD.

PASG financial position

At the end of fiscal 2025 (December 31, 2025), Passage Bio had total assets of $62.3 million (down 39.2% from a year earlier), total liabilities of $43.5 million and shareholders' equity of $18.8 million. It held $46.3 million in cash and short-term investments against $24.0 million of debt, a net cash position of $22.3 million. Its current ratio was 2.07. In the latest quarter (ended June 30, 2026) total assets were $25.2 million and equity $4.5 million.

Related: PASG income statement, PASG cash flow statement, PASG key metrics. See the PASG stock overview for the latest quote and news.

PASG balance sheet FAQ

What are Passage Bio's total assets?

Passage Bio reported total assets of $62.3 million at the end of fiscal 2025 (December 31, 2025), compared with $102.4 million a year earlier.

How much debt does Passage Bio have?

Passage Bio had $24.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 1.28.

How much cash does Passage Bio have?

Passage Bio held $46.3 million in cash and short-term investments at the end of fiscal 2025; with $24.0 million of debt that is net cash of $22.3 million.

What is Passage Bio's book value?

Passage Bio's shareholders' equity (book value) was $18.8 million at the end of fiscal 2025, or $5.91 per share.

What is Passage Bio's current ratio?

Passage Bio had current assets of $47.8 million and current liabilities of $23.1 million, a current ratio of 2.07 (it can cover its short-term obligations).

Biotechnology: balance sheet